Published in final edited form as:

AIDS Rev. 2019 ; 21(1): 11–22. doi:10.24875/AIDSRev.19000003.

HIV-1 and Compromised Adult Neurogenesis: Emerging Evidence for a New Paradigm of HAND Persistence

Raj Putatunda^{1,2}, Wen-Zhe Ho¹, Wenhui Hu^{1,2}

¹Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA

²Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA

Abstract

The face of the HIV-1/AIDS pandemic has changed significantly thanks to the development of antiretroviral therapy (ART) regimens. Unfortunately, several HIV-associated comorbidities continuously occur in the clinical population, most notably HIV-associated neurocognitive disorders (HAND). While many molecular and cellular mechanisms have been characterized by describing HAND pathology (specifically neuroinflammatory insults and oxidative stress) in the ART era, compromised adult neurogenesis is emerging as a potential new mechanism. Neurogenesis is a dynamic process that generates new neurons and glial cells from neural stem cells (NSCs) and neural progenitor cells (NPCs) in specific areas of the brain. There are increasing observations that HIV-1 can productively and non-productively infect NSCs and NPCs. HIV-1 proteins and/or secondary immune/inflammatory responses impair the initial differentiation process of NSCs to NPCs, restrict neuronal lineage differentiation, and aberrantly promote astrocytic lineage differentiation. Recent studies with HIV-1 transgenic animal models demonstrate varying degrees of adult neurogenic deficits, which correlate with milder to moderate forms of neurocognitive impairments. The neurogenic dysfunction underlying HAND highlights the importance of developing potential therapeutics to restore adult neurogenic homeostasis in HIV-1 patients.

Keywords

HIV-1 latency; HIV-associated neurocognitive disorders; Neurogenesis; Neural stem cell; Antiretroviral therapy

Correspondence to: Wenhui Hu, Center for Metabolic Disease Research, Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, PA 19140, Philadelphia, USA, whu@temple.edu.

Conflicts of interest
None.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Introduction

Persistent HIV-associated neurocognitive disorders (HAND) in the antiretroviral therapy (ART) era

In the past three decades, several scientific advances have helped to convert HIV-1 infection from a fatal disease to a chronic, yet manageable disorder. One of the most important advances in HIV-1 research is the development of ART in 1996. Once administered as a monotherapy, new ART regimens have evolved so that several drugs could be administered with a lower pill burden to inhibit HIV-1 infection/replication at several stages of the viral life cycle. For example, nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs/NNRTIs) were developed to inhibit the reverse transcription of the proviral RNA into cDNA. Integrase inhibitors were developed to hamper viral cDNA integration into the host genome, while a plethora of proteases and viral entry inhibitors block HIV-1 entry as well as viral protein production. As a result, mortality rates from HIV-1 infection/AIDS progression and its subsequent opportunistic infections have decreased significantly in the ART era.

However, even with the ART, patients began developing varying levels of cognitive dementia, which came to be collectively coined as HAND. Under the Frascati criteria, HAND is a spectrum of neurocognitive impairments that are described as an asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD)¹. Patients are diagnosed with ANI if they have developed slight impairments in more than two neurocognitive domains, with very minimal alterations in daily lifestyles. Patients with MND also show slight impairments in more than two neurocognitive domains. However, these impairments impede with their everyday lifestyles. Patients with HAD have robust impairments in more than two neurocognitive domains and are completely unable to function independently.

Since the start of the ART era, the clinical presentation of HAND has evolved. Before the development of ART, HAD was the most common, and the deadliest form of HAND. During a clinical study conducted by the Multicenter AIDS Cohort Study (MACS), 20% of all HIV-1 patients enrolled before 1991 met the diagnostic criteria for HAD². However, between 2001 and 2003, only 5% of the enrolled HIV-1 patients manifested HAD³. During the pre-ART era, an HIV-1 patient with HAD only had a 5-month life expectancy⁴. In contrast, the average life expectancy of a HAD patient diagnosed between 1996 and 2000 was 38.5 months⁴. Extrapyramidal motor abnormalities such as bradykinesia, tremors, and aberrant rigidity, as well as subcortical dysfunction such as psychomotor slowing and robust cognitive disabilities, are rare in ART-controlled HIV-1 patients⁵. Thankfully, these promising epidemiological studies showed that ART remarkably diminished HAD incidence. While this data are optimistic, 15–55% of all HIV-1 patients can still develop milder/moderate forms of HAND².

Atrophic brain signature in HAND patients

While ANI or MND are not quite as severe as HAD, patients with these forms of HAND can develop worsened cognitive prognosis. The results from the central nervous system (CNS)

HIV-1 Antiretroviral Therapy Effects Research (CHARTER) group showed that patients with ANI at baseline were more likely to develop worsened cognitive prognosis at follow-up evaluations than patients with normal cognitive performance. This suggests that there are microstructural alterations in the brain which can develop even before symptoms manifest. In fact, imaging studies demonstrated that HIV-1 can induce structural changes in the brain almost 100 days after primary infection, before the onset of symptoms⁶. Abnormal white matter volume is significantly associated with the severity of HAND, while patients with HAD or MND also have smaller gray and white matter volumes than neurocognitively unimpaired HIV-1 patients⁷. A recent study showed that specific frontal white matter atrophy contributes to ANI, while more widespread subcortical atrophy is associated with MND⁸. These specific types of brain atrophy could possibly predict neurocognitive morbidity in HIV-1 patients⁹.

Integrative biomarkers for biological aging and HAND

Risk factors for HAND have also evolved^{5,10,11}. In the pre-ART era, high levels of plasma and cerebrospinal fluid (CSF) HIV-1 RNA, low CD4⁺ T-cell counts, and robust immunosuppression due to infection all correlated with an increased risk for dementia. However, in the post-ART era, HIV-1 related immunosuppression and high viral loads are no longer relevant in determining the progression of HAND. Instead, older age, illicit substance abuse, low CD4 nadir counts, depression, hypertension, diabetes, and high cholesterol levels all correlate with worsened HAND diagnoses, especially in older HIV-1 patients^{5,12,13}. To assess all of these current risk factors, several biomarkers are currently being evaluated for their reliability in accurately diagnosing the stages of HAND¹³. Biomarkers for immune activation include elevated plasma and CSF levels of sCD163, sCD14, interleukin (IL)-1 α , tumor necrosis factor α (TNF α), MMP2, MCP1, osteopontin, and fractalkine^{14,15}. Additional CSF biomarkers for HAND include molecules involved in cellular metabolisms, such as CSF TCA cycle substrates, fatty acids, and triglycerides^{5,10,16}.

With the optimization and wider availability of ART drugs, it is imperative to acknowledge the contribution of premature aging to the evolution of HAND¹⁷. In fact, approximately 73% of HIV-1 patients will be over 50 years old by 2030^{18,19}. Preliminary data from the CHARTER study demonstrate that HIV-1 infection and older age may synergistically lead to worsened neuropsychiatric performance than either factor alone²⁰. In addition, several clinical studies have also shown that HIV-1 patients with pre-existing cardiovascular complications have an approximately six-fold higher chance of developing cognitive impairment than HIV-1 patients with no cardiovascular abnormalities^{21,22}. Therefore, therapeutics for HIV-1 and HAND need to take aging into account during administration²³.

Molecular and cellular pathogenesis underlying HAND

The development of ART has significantly changed the histopathological progression of HAND. For example, patients with HAD exhibited varying degrees of cerebral encephalitis, as assessed postmortem. After the start of the ART era, the incidence of encephalitis in HIV-1 patients decreased from 54% to 15%²⁴. While the overt neuronal loss was a histological characteristic of HAND patients in the pre-ART era, the veracity of this

assumption is waning. While neurons themselves are not completely lost, their functionality is significantly compromised^{25,26}. The mechanisms by which HIV-1 causes neuronal damage, as well as systemic neurophysiological alterations, are still not completely understood. At present, the general consensus is that HIV-1 infects the brain through a Trojan Horse-type mechanism. HIV-1 infects CD4⁺ T-lymphocytes and monocytes in the peripheral circulatory system. This infection is directly dependent on the CD4 receptor in addition to viral coreceptors CXCR4 and CCR5²⁷. Once peripheral HIV-1 infection is established, it takes some time for the virus to invade the CNS. This CNS infiltration is attributed to infected monocytes crossing the blood–brain barrier and then actively releasing viruses and viral particles into the CNS. This secondary infection leads to the activation of resident glial cells, such as microglia and astrocytes. These activated cells generate an inflammatory environment through the release of several viral proteins (such as Tat, gp120, and Rev) and pro-inflammatory cytokines. These factors may damage neurons through the production of reactive oxygen species, membrane depolarization, and disruption in neurotransmitter homeostasis²⁷.

While HIV-1 infection and subsequent inflammatory insults can contribute to the downstream CNS damage, there is an increasing set of literature implicating ART drugs in HAND progression. In fact, ART drugs that are capable of penetrating the CNS at a higher efficiency have been correlated with worsened cognitive status^{28–30}. One *in vitro* study demonstrated that 15 different ART drugs had varying degrees of neuronal toxicity, as assessed by cell viability assays, neuronal arborization analyses, and mitochondrial membrane potential measurements³¹. The findings of aberrant mitochondrial membrane potential were notable, as they raised the possibility that ART drugs induced oxidative stress in neurons. Another study demonstrated that one NRTI (AZT) and two protease inhibitors (Ritonavir and Saquinavir), both individually and synergistically, induced varying degrees of oxidative stress and neuronal damage in the CNS, while astrocytes remained spared from damage³². This was supported by histological evidence that SIV-infected pigtail macaques treated with ART had more synaptodendritic damage than ART-naïve SIV-infected macaques³². Further investigation using Ritonavir and Saquinavir demonstrated that these two front-line protease inhibitors induced the integrated stress response in neurons, which could be pharmacologically reversed with a drug that inhibited the phosphorylation of eIF2 α ³³. Another study demonstrated that Ritonavir and Lopinavir hampered oligodendrocyte survival and maturation at the *in vitro* and *in vivo* levels³⁴. Interestingly, AZT had no effects on oligodendrocyte integrity. Further Western blotting studies on prefrontal cortical brain lysates revealed that HIV-1 patients on ART had significant decreases in myelin basic protein expression than ART-naïve HIV-1 patients and uninfected patients³⁴. While this body of literature is relatively small, these studies demonstrate that front-line ART therapies damage the CNS through mechanisms such as oxidative stress, activating the integrated stress response, and inducing varying degrees of white matter damage, thus possibly contributing to HAND progression.

Given these interesting findings, strategies involving the switching and simplification of ART regimens (one or less NRTIs, totaling < 3 drugs) have been extensively explored to mitigate drug-induced toxicity, viral resistance, and adherence interruption^{35–39}. However, the benefits of simplified ART regimens remain controversial because they may be less

effective in suppressing CNS viral loads and improving neurological function^{40–42}. A long-term three-decade retrospective study using a large cohort of 4992 HIV-positive patients with regimen switching protocols demonstrated that neurocognitive deficits do not necessarily improve in most cases, even if systemic viral suppression is successfully achieved⁴³. Therefore, further prospective long-term studies are warranted to optimize a “better” ART regimen.

While many studies support the theory of indirect Trojan-Horse mechanism for HIV-1 induced neuronal damage and ART-induced CNS dysfunction, the notion of productive neuronal infection by HIV-1 remains controversial. This could be explained by two reasons. One might be the lack of CD4 expression on neurons, even though they express the HIV-1 coreceptors CXCR4 and CCR5²⁷. While CD4-independent mechanisms of infection may exist, they are not as commonly reported in literature⁴⁴. Another explanation could be the higher levels of HIV-1 specific host restriction factors in neurons. Several well-characterized HIV-1 host restriction factors include the tripartite motif 5 (TRIM5) family of proteins, the Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 family of proteins, the myxovirus resistance protein, Bone Marrow Stromal Cell Antigen 2 (BST2, or Tetherin), and SAMHD1⁴⁵. While expression of these host restriction factors is highly restricted to immune-lineage cells, the Human Protein Atlas revealed higher levels of expression of TRIM5 and SAMHD1 in neurons than those in glial cells, which may explain why HIV-1 infection is undetectable in neurons²⁷.

HIV-1 latent infection in the CNS

The formation of a latent reservoir allows HIV-1 to persist throughout a patient’s lifetime, even while adhering to ART. Several cellular reservoirs have been characterized to harbor low-level chronic HIV-1 infection, which contributes to a barrier for a sterile HIV-1 cure. Examples of these reservoirs include: resting memory CD4⁺ T-lymphocytes, microglia, monocytes, macrophages, and astrocytes. Out of all these reservoirs, the resting memory CD4⁺ T-lymphocytes contain the highest HIV-1 load.

During the initial stages of CNS infiltration, HIV-1 predominantly infects perivascular macrophages, microglia, and astrocytes. These CNS cells satisfy most of the criteria for an HIV-1 reservoir, as described by Blankson et al.⁴⁶. For example, these cells have been shown to harbor integrated HIV-1 provirus, as demonstrated through methods such as *in situ* hybridization and laser capture microdissection coupled with PCR⁴⁷. The perivascular macrophages have a half-life of about 3 months⁴⁸, while microglial cells and astrocytes have a half-life ranging from several months to years, potentially upward of an entire lifetime⁴⁹. Furthermore, these cells harbor the specific molecular machinery to facilitate the HIV-1 provirus into a latent state. For example, the CNS-derived HIV-1 long terminal repeat (LTR) promoter has lower basal transcriptional activity due to mutations in the core promoter region⁵⁰. Robust suppression of SIV LTR activity has also been corroborated in SIV infection models, as IFN- β induced the expression of a dominant-negative form of C/EBP- β in the CNS⁵¹. In HIV-1 postmortem brain specimens, CTIP2, HP1, MeCP2, and HDAC1 levels were all elevated, giving rise to the possibility that they may play a role in HIV-1 transcriptional silence in the CNS⁵².

Since astrocytes are the most abundant cell type in the CNS, their roles in HAND have been extensively studied. It remains controversial whether astrocytes can be productively and/or latently infected by HIV-1. Early immunohistochemical studies using postmortem brain tissue from HAD patients demonstrated the presence of HIV-1 proteins in hippocampal astrocytes⁵³. The highly sensitive PCR analysis of laser-captured single astrocytes revealed HIV-1 DNA in up to 19% of astrocytes from HAD patients⁵⁴. Even in asymptomatic individuals, HIV-1 DNA was detected in laser-captured astrocytes⁴⁷. However, most *in vivo* studies only demonstrated the detection of early HIV-1 transcripts, such as Nef⁵⁵. *In vitro* studies showed contradicting conclusions. For example, while primary astrocytes or astrocytic cell lines demonstrated either productive⁵⁶ or non-productive⁵⁷ infection, Boutet et al. reported that astrocytes remained completely resistant to HIV-1 infection⁵⁸. Nevertheless, persistent HIV-1 infection in astrocytic cell lines⁵⁹ or primary human astrocytes⁶⁰ may contribute to the pathogenesis of HAND in the ART era⁶⁰. Endocytosis⁵⁶ and cell-to-cell interactions⁴⁴ have been identified as possible mechanisms of HIV-1 entry into astrocytes. The concept of latent HIV-1 infection in astrocytes has been also controversial. Early studies in stable cell lines after HIV-1 cDNA transfection demonstrated latency and reactivation-like properties⁶¹. Subsequent studies with latency-reversing agents showed the epigenetic regulation of HIV-1 latency in primary astrocytes⁵⁷ and human neural stem cells (NSC)-derived astrocytes⁶². Recent reports demonstrated that human astrocytes sustain long-term productive HIV-1 infection without the establishment of reversible viral latency⁶⁰. Although the frequency of HIV-infected astrocytes is very low, the large number of total astrocytes in the brain, cell-to-cell transmission, and long-term HIV-1 infection may justify the important contribution of long-lived astrocytes to HAND persistence.

The inflammatory and immunological regulation of adult neurogenesis

Adult neurogenesis describes the generation of new neurons and glial cells mainly in two specific locations in the adult CNS: the subventricular zone (SVZ) lining the lateral ventricles and the subgranular zone (SGZ) lining the inner dentate gyrus of the hippocampus. In the SVZ neurogenic niche, slowly proliferating radial glial cells (GFAP expressing B cells) differentiate into rapidly proliferating transit-amplifying cells (Mash1 expressing C cells), which then differentiate into neuroblasts (doublecortin-expressing A cells)⁶³. These neuroblasts then tangentially migrate to the olfactory bulb using a tunnel-like astrocytic network termed the rostral migratory stream. After migration, these neuroblasts detach from the stream, and terminally differentiate into either periglomerular neurons or olfactory granule cells, which radially integrate into the olfactory bulb to modulate olfactory stimuli processing⁶³. In the SGZ, the neurogenic process is similar, except the migration distance of NSC/neural progenitor cells (NPC) is much shorter than that for SVZ neurogenesis. As the NSCs terminally differentiate into mature dentate granule neurons, they radially migrate into the granule cell layer of the dentate gyrus and extend mossy fibers toward the CA3 region of the hippocampus. In both neurogenic niches, NSCs represent only a small population of quiescent and slowly dividing cells, whereas NPCs are a larger population of amplifying, rapidly dividing cells⁶³.

NSCs/NPCs are always mixed in culture conditions because NSCs continuously differentiate into NPCs. *In vivo* studies have identified the presence of quiescent (type Ia) and actively

proliferating NSCs (type Ib)⁶⁴. The types of cells in each stage can be identified with cell-specific markers (Fig. 1). For example, GFAP expression with Sox2 and/or nestin expression is characteristic for NSCs (GFAP⁺), while NPCs only express Sox2 and/or nestin. Type 1b NSCs are Nestin⁺/GFAP⁺/Sox2⁺/Ki67⁺ immunoreactive, while type 1a NSCs are Nestin⁺/GFAP⁺/Sox2⁺/Ki67⁻. Mature astrocytes express GFAP and S100 β ⁺, while oligodendrocytes express PLP, MBP, and O4.

The adult neurogenic process is regulated by many intrinsic and extrinsic factors, up to but not including mood states, exercise, and injury. One of the most important modulators of adult neurogenesis is neuroinflammatory stimuli⁶⁵. In physiological conditions, microglia are immune cells that surveil the CNS for external pathogens as well as endogenous damage. Interestingly, there is a high concentration of microglia in the SVZ and SGZ niches, indicating that these cells tightly regulate the neurogenic process^{66,67}. During CNS injury, microglia secrete a variety of cytokines and chemokines that can modulate adult neurogenesis.

IL-1 α has been shown to promote the differentiation of mesencephalic NSCs into dopaminergic neurons while having an inhibitory effect on postnatal hippocampal neurogenesis⁶⁸. IL-1 β decreased NSC proliferation and neuronal differentiation, which was reversed by treatment with IL-1 receptor antagonist⁶⁹. However, IL-1 β treatment promotes astrocytic lineage differentiation⁷⁰. Most studies involving TNF- α showed increased glial lineage differentiation and decreased neuronal lineage differentiation. For example, treating human fetal cortical NSCs/NPCs with TNF- α induced higher levels of apoptosis promoted glial lineage differentiation, and hampered neuronal differentiation⁷¹. However, in mouse SVZ NSCs, treatment with TNF α resulted in NF κ B-dependent neuronal lineage differentiation, which could be reversed by an NF κ B inhibitor⁷². These conflicting reports could be attributed to differences in animal species where the NSCs/NPCs were derived from, the type of NSCs/NPCs (embryonic vs. adult) used, as well as the concentrations of TNF- α tested. Human hippocampal NSC treatment with IFN- γ did not alter neuronal lineage differentiation but increased astrocytic lineage differentiation⁷³. However, in rat striatal NPCs, IFN- γ treatment reduced NSC/NPC proliferation and enhanced apoptosis⁷⁴.

These inflammatory mediators play an important role in modulating the spread of HIV-1 infection. IL-1 α and IL-1 β have been shown to reactivate latent HIV-1 in U1 cells in a dose-dependent manner⁷⁵. In addition, EcoHIV infection levels were higher in IL-1 receptor knockout mice than wild-type control mice⁷⁶. TNF α has the ability to reactivate HIV-1 expression in latently infected cells through an NF κ B dependent mechanism⁷⁷, while IFN- γ has been shown to enhance natural killer cell and CD8⁺ T cell responses to combat HIV-1 infection⁷⁸. Finally, IL-4 has been shown to increase HIV-1 replication in CD4⁺ T-cells⁷⁹. These studies suggest that inflammatory mediators not only directly impair neurogenesis but also facilitate the spread of HIV-1 in the CNS. Therefore, inflammatory modulation of adult neurogenesis is likely to be a contributor to the progression of HAND.

Productive and latent HIV-1 infection in NSCs

There is an increasing body of literature demonstrating active and latent HIV-1 infection in NSCs that may serve as a new reservoir for HIV-1^{80–82}. Several prerequisites are needed for a target cell to serve as an HIV-1 reservoir. The first is that the cells must contain a replication-competent integrated provirus. Second, the virus must have a mechanism for escaping biochemical decay and establish long-term persistence. The third requirement is that the cells must have the molecular machinery to help the HIV-1 provirus to enter a transcriptionally silent (aka. latent) state. The fourth requirement is that the cells must be capable of reactivating the latent provirus to re-seed new rounds of infection. These sum up the active infection and reversible latency requirements that are characteristic of most HIV-1 cellular reservoirs⁴⁶.

Early studies using both CXCR4 and CCR5-tropic strains of HIV-1 showed that primary human neuroblasts derived from fetal olfactory tissue and a neuroblastoma cell line are susceptible to HIV-1 infection⁸³. Another study utilizing a human NSC line (HNSC.100) demonstrated effective HIV-1 infection⁸⁴. Viral release lasted for over 2 months, and the cell-associated HIV-1 markers (proviral DNA and early HIV-1 transcripts) persisted during the entire observation period (115 days), suggesting the presence of a long-term productive and latent infection⁸⁴. These previous findings were further validated by a recent study utilizing an immortalized human embryonic ReNcell VM NSC line and a mouse NE-4C NSC line infected with HIV-1 and EcoHIV, respectively⁸⁵. While these findings were interesting, these studies were performed in the immortalized cell lines, which are not as clinically relevant as human primary NSCs.

One early study⁸⁶ that utilized primary NSCs to assess productive and latent HIV-1 infection was conducted by Lawrence et al. in 2004. They showed that two CXCR4-tropic HIV-1 strains (HIV_{NL4-3} and HIV_{IIIB}) were capable of infecting human fetal brain-derived primary NSCs/NPCs *in vitro*. This infection was productive, as a viral release from these cells peaked at 3–6 days post-infection. Even though viral production was undetectable after 10 days post-infection, treatment with TNF- α could reactivate the virus in the HIV-1-infected NSCs/NPCs⁸⁶. These findings were significant, as they implicated NSCs for the first time as a possible new latent reservoir in the CNS, through which HIV-1 latent infection can persist, and be reversed through latency reversing agents such as TNF α . Interestingly, this latency formation was independent of the HIV-1 entry receptors because transfection of an HIV-1 pNL4-3 vector induced similar latency-like infection⁸⁶.

A recent study⁸⁷ with human primary NSCs expanded on these initial *in vitro* findings to assess whether a CCR5 tropic viral strain (HIV-1_{BaL}) could productively infect human fetal NSCs/NPCs. This study revealed that HIV-1 can not only productively infect NSCs, but also transmit from the infected NSCs to non-infected NSCs⁸⁷. This observation bolstered the notion that NSCs are the host for HIV-1 propagation, although the types of the propagating cells after initial HIV-1 infection of NSCs remain to be determined. A new study demonstrated that EcoHIV was capable of infecting mouse primary NSCs/ NPCs⁸⁵. Interestingly, both neurons and glial cells differentiated from EcoHIV-infected mouse primary NSCs/NPCs retained high copies of integrated and latent EcoHIV proviral DNA at

2 weeks post-infection. This latent reservoir (integrated proviral DNA) remained responsive to treatment with the latency-reversing agent SAHA by expressing HIV-1 RNA transcripts and p24 protein⁸⁵. Although the differentiated cell types (neurons and astrocytes or oligodendrocytes) on reactivation to retain HIV-1 infection need further characterization, to delineate whether NSC-derived astrocytes are HIV-1 latent reservoir would be important in understanding the pathogenesis of HAND persistence. Latently HIV-1-infected astrocytes have been shown to transmit the virus to other cell populations, such as microglia/macrophages and T cells to induce a full productive infection⁸⁸. Astrocytes are capable of retaining long-term productive infection⁶⁰. In addition, the presence of the integrated HIV-1 DNA in fully differentiated neurons is also an interesting finding, supporting earlier reports of integrated HIV-1 DNA in the neurons of pediatric HIV-1 patients^{27,89}.

While many of these pioneering *in vitro* studies have provided evidence that HIV-1 can productively and latently infect human NSCs^{85–87}, only one clinical study demonstrated the presence of the HIV-1 proviral genome in both the SVZs and SGZs of four pediatric AIDS patients⁹⁰. Therefore, more solid *in vivo* evidence is urgently needed to corroborate these initial findings. The recent development of RNA/DNA Scope technology⁹¹ and digital droplet PCR analysis⁹² may allow for more sensitive detection of HIV-1 DNA and RNA in the CNS cellular reservoirs in ART-controlled HIV-1 patients. Alternatively, human brain organoids derived the induced pluripotent stem cells may serve as a novel *ex vivo* model to validate HIV-1 infection in human primary NSCs⁹³. Since only a small number of GFAP⁺ cells are susceptible to HIV-1 infection, and NSCs express GFAP, a better understanding of the similarity and diversity for HIV-1 infection between NSCs and astrocytes should provide optimized therapeutics for the HIV-1 patients with HAND.

Neurogenic deficits by HIV-1 infection and viral proteins

Persistent HIV-1 infection in NSCs may alter their functional features such as self-renewal, tripotential differentiation, and survival. Early studies in human primary NSCs and hippocampal slices demonstrated that HIV-1 coat proteins or the CSF from HIV-1 patients inhibited the differentiation of NSCs into NPCs by inducing NSC quiescence⁹⁴. Early studies in an HNSC.100 cell line showed that HIV-1 infection inhibited neuronal differentiation and promoted astrocytic lineage differentiation⁸⁴. A recent study showed that HIV-1 infection not only decreased neuronal lineage differentiation but also compromised the morphological arborization of differentiated neurons⁸⁵. However, a recent *in vitro* study has shown that active HIV-1 infection of human NSCs promotes both neuronal and astroglial lineage differentiation⁸⁷. This discrepancy may result from different viral strains and experimental conditions utilized.

The first study to assess the effects of HIV-1 proteins on neurogenesis was conducted in 2007 by Okamoto et al.⁹⁵. While rat NSCs treated with HIV-1 gp120 did not have apoptosis, their proliferation was significantly reduced at the *in vitro* and *in vivo* levels due to stimulation of the p38-MAPK signaling cascade⁹⁵. However, gp120 had little effect on the neuronal or astrocytic lineage differentiation. Further studies examining the role of gp120 on neurogenesis were conducted with a GFAP-gp120 transgenic mouse⁹⁶, in which the gp120 is constitutively expressed in GFAP⁺ astrocytes and NSCs. Initial analysis revealed significant

astrogliosis and synaptodendritic damage in GFAP-gp120 transgenic mouse when compared to non-transgenic control mice⁹⁶. While this study was essential to understanding the role of gp120 in HIV-1-induced neuropathology, only mature astrocytes were examined. Since NSCs also express GFAP, adult neurogenesis could also be potentially impaired in these mice. A more recent study validated the expression of gp120 in NSCs using immunohistochemical analysis⁹⁷. GFAP-gp120 mice had significant decreases in NSC proliferation and neuroblast/neuron production in the SGZ, which were rescued by exercise or paroxetine treatment. Interestingly, using retroviral labeling technology, they showed that newborn dentate granule neurons in GFAP-gp120 transgenic mice exhibited increased dendritic arborization and length when compared to newborn dentate granule neurons in the non-transgenic littermates. This aberrant initial dendritic outgrowth was also rescued by exercise and paroxetine treatment⁹⁷. These deficits in adult neurogenesis could be rescued by modulation of the endocannabinoid system. Treating GFAP-gp120 mice with the CB2 agonist AM1241 enhanced NSC/NPC proliferation, decreased apoptosis, and promoted higher levels of neuronal differentiation when compared to untreated GFAP-gp120 mice⁹⁸. In addition, the genetic deletion of the fatty acid amide hydrolase in GFAP-gp120 mice rescued gp120-induced neurogenic deficits in a similar manner as AM1241 treatment⁹⁹. These findings are consistent with previous reports implicating the neuroprotective role of endocannabinoid signaling in the CNS¹⁰⁰.

HIV-1 Tat protein has been reported to impair adult neurogenesis. The first *in vitro* study implicating Tat in neurogenesis showed that increasing doses of Tat decreased secondary neurosphere size, decreased NSC proliferation, and decreased neuronal lineage differentiation without inducing any changes in NSC viability¹⁰¹. The deficits in NSC proliferation are attributed to the decreased cyclin D1 expression and ERK1/2 pathway activation¹⁰¹. Another *in vitro* study demonstrated that Tat impaired the proliferation of human embryonic NSCs through disruption of the p38/JNK MAPK signaling pathways, which was attenuated by pre-treatment with platelet-derived growth factor-BB¹⁰². To understand the role Tat plays in modulating neurogenesis at the *in vivo* levels, the doxycycline-inducible GFAP-Tat transgenic mice were generated, wherein the tetracycline responsive element is placed ahead of the mouse GFAP promoter, allowing for Tat expression in GFAP⁺ cells on doxycycline induction¹⁰³. On treatment with doxycycline, the inducible GFAP-Tat mice exhibited a smaller NSC pool, decreased NSC/NPC proliferation, decreased neuronal lineage differentiation, and increased astrocytic lineage differentiation, when compared to untreated GFAP-Tat mice⁸¹. These deficits are consistent with the neurogenic studies conducted in GFAP-gp120 mice^{97–99}. These mice were also used to assess the mechanism behind the increased preference for astrocytic lineage differentiation of NSCs. The authors found that increased STAT3 activation in GFAP-Tat mice leads to an increased GFAP expression in NSCs¹⁰⁴, which further confirmed an *in vitro* study elucidating the role of Tat in inducing astrocytic lineage differentiation in cortical NSCs/NPCs⁷¹.

Correlation of neurogenic deficits with cognitive abnormalities

While the GFAP-gp120 mouse and doxycycline-inducible GFAP-Tat mouse were integral in their roles for elucidating the effects of gp120 and Tat on neurogenesis, virtually no

behavioral studies have been conducted in parallel with the *in vivo* neurogenesis experiments^{81,97–99}. However, some studies have shown varying degrees of neurocognitive deficits in these mice. For example, while GFAP-gp120 mice had no deficits in novel object recognition or novel object location tasks, they showed deficits in an object-in-place recognition task¹⁰⁵. This same study also showed that GFAP-gp120 mice had no defects in spatial learning and memory in a Barnes maze behavioral task, as assessed by the delayed time to enter the target hole and number of reference errors made¹⁰⁵. However, the doxycycline-inducible GFAP-Tat mice showed different results as these animals had robust deficits in contextual fear conditioning, Morris water maze escape tasks, and Barnes maze latency to escape^{106–109}. These spatial memory deficits correlate with selective loss of the vulnerable CA1 hippocampal interneurons¹⁰⁹. Collectively, these observations indicate that Tat may have more of a neurotoxic effect on the cognitive outcome than gp120. However, the correlation of adult neurogenic impairment with the neurocognitive dysfunctions in HIV-1 transgenic animals or HIV-1 infected patients has not yet been evaluated.

Outstanding questions and future directions

Collectively, the literature shows that adult neurogenesis is compromised in HIV-1 infected patients in both the pre- and post-ART eras^{90,110}. NSCs are capable of being productively and latently infected by HIV-1. It is likely that the integrated proviral DNA may persist as the NSCs differentiate into neurons, astrocytes, or oligodendrocytes. Or, the latent provirus may be reactivated as the NSCs differentiate into rapidly amplifying NPCs, spreading the infection to neighboring infiltrating immune cells and astrocytes. This secondary infection could re-seed the latent reservoir in NSCs or damage the NSCs and their progeny cells (Fig. 2).

The HIV-1 proteins gp120 and Tat exert differential effects on adult neurogenesis at the molecular, cellular, and neurobehavioral levels. However, most of the reported studies focused on single viral proteins (Tat or gp120) in a specific cellular type (GFAP⁺ astrocytes and/or NSCs). HIV-1 patients in the ART era have the entire HIV-1 proviral genome integrated into their cells. To mimic the persistent and latent HIV-1 infection during the ART era, two rodent models have been generated: the HIV-1 Tg26 mouse¹¹¹ and the HIV-1 transgenic rat¹¹². Both models contain multiple copies of a replication-deficient HIV_{NL4-3} strain integrated into their cells and express various degrees of HIV-1 transcripts in different organs/tissues^{111,112}, particularly in the neurogenic zones⁸⁰. Even though spatial learning and memory deficits have been demonstrated in the HIV-1 transgenic rat¹¹³, they have not been directly correlated with alterations of adult neurogenesis. Our recent *in vitro* and *in vivo* study demonstrated that HIV-1 Tg26 mice exhibited significant deficits in the early- and late-stage neurogenesis⁸⁰. It would be interesting to determine how neurogenesis is modulated in rodent models with acute or chronic infection (i.e., direct infection with Eco-HIV in wild-type mice or HIV-1 infection in humanized mouse models with engrafted human brain organoids). Finally, it would be of importance to assess any gender-specific differences in adult neurogenesis in the context of HIV-1 infection. Given that women make up a majority of the HIV-1-infected population worldwide and clinical studies evaluating the incidence of HIV-1/HAND in male and female patients have been inconsistent¹¹⁴, modeling any possible gender-specific neurogenesis deficits in animal models of HIV-1 disease would

significantly benefit the HAND research. Finally, the effects of neurogenesis in the aging HAND population should be evaluated. Since the prevalence of HIV-1 infection in patients aged 50 and older is increasing, and hippocampal neurogenesis depletes with aging, understanding the role of aging in the development of HAND is of clinical relevance and significance.

Acknowledgments

Funding

National Institutes of Health (R01AI145034 to W.H., T32MH079785 to R.P.).

References

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007;69:1789–99. [PubMed: 17914061]
2. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS cohort study. *Neurology*. 1993;43:2245–52. [PubMed: 8232937]
3. Becker JT, Kingsley LA, Molsberry S, et al. Cohort profile: recruitment cohorts in the neuropsychological substudy of the multicenter AIDS cohort study. *Int J Epidemiol*. 2015;44:1506–16. [PubMed: 24771276]
4. Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. *AIDS*. 2003;17:1539–45. [PubMed: 12824792]
5. Sacktor N. Changing clinical phenotypes of HIV-associated neurocognitive disorders. *J Neurovirol*. 2018;24:141–5. [PubMed: 28752495]
6. Ragin AB, Wu Y, Gao Y, et al. Brain alterations within the first 100 days of HIV infection. *Ann Clin Transl Neurol*. 2015;2:12–21. [PubMed: 25642430]
7. Alakkas A, Ellis RJ, Watson CW, et al. White matter damage, neuroinflammation, and neuronal integrity in HAND. *J Neurovirol*. 2018 DOI: 10.1007/s13365-018-0682-9.
8. Nichols MJ, Gates TM, Soares JR, et al. Atrophic brain signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection. *AIDS*. 2019;33:55–66. [PubMed: 30325766]
9. Popov M, Molsberry SA, Lecci F, et al. Brain structural correlates of trajectories to cognitive impairment in men with and without HIV disease. *Brain Imaging Behav*. 2019 DOI: 10.1007/s11682-018-0026-7.
10. Marzel A, Kouyos RD, Reinschmidt S, et al. Dietary patterns and physical activity correlate with total cholesterol independently of lipid-lowering drugs and antiretroviral therapy in aging people living with human immunodeficiency virus. *Open Forum Infect Dis*. 2018;5:ofy067. [PubMed: 29687016]
11. Thakur KT, Boubour A, Saylor D, et al. Global HIV neurology: a comprehensive review. *AIDS*. 2019;33:163–84. [PubMed: 29547440]
12. Rajasuriar R, Palmer C, Abdel-Mohsen M, Kamaruzzaman SB. Integrative biomarkers of biologic aging in HIV. *AIDS*. 2019;33:345–7. [PubMed: 30562173]
13. Olivier IS, Cacabelos R, Naidoo V. Risk factors and pathogenesis of HIV-associated neurocognitive disorder: the role of host genetics. *Int J Mol Sci*. 2018;19:E3594. [PubMed: 30441796]
14. Moreno-Villanueva M, Bürkle A. Epigenetic and redox biomarkers: novel insights from the MARK-AGE study. *Mech Ageing Dev*. 2019;177:128–34. [PubMed: 29969595]
15. Bürkle A, Moreno-Villanueva M, Bernhard J, et al. MARK-AGE biomarkers of ageing. *Mech Ageing Dev*. 2015;151:2–12. [PubMed: 25818235]
16. Yeoh HL, Cheng AC, Cherry CL, et al. Immunometabolic and lipidomic markers associated with the frailty index and quality of life in aging HIV+ men on antiretroviral therapy. *EBioMedicine*. 2017;22:112–21. [PubMed: 28754302]

17. Nasi M, De Biasi S, Gibellini L, et al. Ageing and inflammation in patients with HIV infection. *Clin Exp Immunol*. 2017;187:44–52. [PubMed: 27198731]
18. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. *Lancet Infect Dis*. 2015;15:810–8. [PubMed: 26070969]
19. Wing EJ. HIV and aging. *Int J Infect Dis*. 2016;53:61–8. [PubMed: 27756678]
20. Mehta SR, Pérez-Santiago J, Hulgán T, et al. Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. *J Neuroinflammation*. 2017;14:72. [PubMed: 28359324]
21. Smit M, van Zoest RA, Nichols BE, et al. Cardiovascular disease prevention policy in human immunodeficiency virus: recommendations from a modeling study. *Clin Infect Dis*. 2018;66:743–50. [PubMed: 29029103]
22. Boyd MA, Mocroft A, Ryom L, et al. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: a prospective analysis of the D: A:D observational study. *PLoS Med*. 2017;14:e1002424. [PubMed: 29112958]
23. Smail RC, Brew BJ. HIV-associated neurocognitive disorder. *Handb Clin Neurol*. 2018;152:75–97. [PubMed: 29604986]
24. Vago L, Bonetto S, Nebuloni M, et al. Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimens: retrospective study of 1597 autopsies. *AIDS*. 2002;16:1925–8. [PubMed: 12351952]
25. McLaurin KA, Li H, Booze RM, Mactutus CF. Disruption of timing: neuroHIV progression in the post-cART era. *Sci Rep*. 2019;9:827. [PubMed: 30696863]
26. Green MV, Raybuck JD, Zhang X, Wu MM, Thayer SA. Scaling synapses in the presence of HIV. *Neurochem Res*. 2019;44:234–46. [PubMed: 29541929]
27. Kovalevich J, Langford D. Neuronal toxicity in HIV CNS disease. *Future Virol*. 2012;7:687–98. [PubMed: 23616788]
28. Etherton MR, Lyons JL, Ard KL. HIV-associated neurocognitive disorders and antiretroviral therapy: current concepts and controversies. *Curr Infect Dis Rep*. 2015;17:485. [PubMed: 25916996]
29. Walker KA, Brown GG. HIV-associated executive dysfunction in the era of modern antiretroviral therapy: a systematic review and meta-analysis. *J Clin Exp Neuropsychol*. 2018;40:357–76. [PubMed: 28689493]
30. Malagurski B, Bugarski Ignjatovi V, Mari D, et al. Neurocognitive profile of HIV-positive adults on combined antiretroviral therapy: a single-centre study in serbia. *Appl Neuropsychol Adult*. 2018;25:513–22. [PubMed: 28665215]
31. Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. *J Neurovirol*. 2012;18:388–99. [PubMed: 22811264]
32. Akay C, Cooper M, Odeleye A, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. *J Neurovirol*. 2014;20:39–53. [PubMed: 24420448]
33. Stern AL, Lee RN, Panvelker N, et al. Differential effects of antiretroviral drugs on neurons in vitro: roles for oxidative stress and integrated stress response. *J Neuroimmune Pharmacol*. 2018;13:64–76. [PubMed: 28861811]
34. Jensen BK, Monnerie H, Mannell MV, et al. Altered oligodendrocyte maturation and myelin maintenance: the role of antiretrovirals in HIV-associated neurocognitive disorders. *J Neuropathol Exp Neurol*. 2015; 74:1093–118. [PubMed: 26469251]
35. McCoy C, Badowski M, Sherman E, et al. Strength in amalgamation: newer combination agents for HIV and implications for practice. *Pharmacotherapy*. 2018;38:86–107. [PubMed: 29105160]
36. Ciccullo A, Baldin G, Capetti A, et al. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. *Antivir Ther*. 2018 DOI: 10.3851/IMP3270.
37. Boswell R, Foisy MM, Hughes CA. Dolutegravir dual therapy as maintenance treatment in HIV-infected patients: a review. *Ann Pharmacother*. 2018;52:681–9. [PubMed: 29442543]
38. Arrabal-Durán P, Rodríguez-González CG, Chamorro-de-Vega E, et al. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human

- immunodeficiency virus 1: effectiveness, safety and costs at 96 weeks. *Int J Clin Pract*. 2017;71:e12968.
39. Calza L, Cafaggi M, Colangeli V, et al. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. *Infect Dis (Lond)*. 2018;50:352–60. [PubMed: 29210336]
 40. Ferretti F, Gianotti N, Lazzarin A, Cinque P. Central nervous system HIV infection in “less-drug regimen” antiretroviral therapy simplification strategies. *Semin Neurol*. 2014;34:78–88. [PubMed: 24715491]
 41. Di Giambenedetto S, Fabbiani M, Quiros Roldan E, et al. Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). *J Antimicrob Chemother*. 2017;72:1163–71. [PubMed: 28093483]
 42. Mondì A, Fabbiani M, Ciccarelli N, et al. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the atLaS pilot study. *J Antimicrob Chemother*. 2015;70:1843–9. [PubMed: 25885326]
 43. Arendt G, Schlonies S, Orhan E, Stüve O. Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience. *J Neurovirol*. 2019 DOI: 10.1007/s13365-018-0701-x.
 44. Li GH, Anderson C, Jaeger L, et al. Cell-to-cell contact facilitates HIV transmission from lymphocytes to astrocytes via CXCR4. *AIDS*. 2015;29:755–66. [PubMed: 25985398]
 45. Jia X, Zhao Q, Xiong Y. HIV suppression by host restriction factors and viral immune evasion. *Curr Opin Struct Biol*. 2015;31:106–14. [PubMed: 25939065]
 46. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. *Annu Rev Med*. 2002;53:557–93. [PubMed: 11818490]
 47. Thompson KA, Cherry CL, Bell JE, McLean CA. Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. *Am J Pathol*. 2011;179:1623–9. [PubMed: 21871429]
 48. Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in human immunodeficiency virus Type I infection. *Retrovirology*. 2012;9:82. [PubMed: 23035819]
 49. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. *Acta Neuropathol*. 2010;119:7–35. [PubMed: 20012068]
 50. Gray LR, Cowley D, Crespan E, et al. Reduced basal transcriptional activity of central nervous system-derived HIV Type 1 long terminal repeats. *AIDS Res Hum Retroviruses*. 2013;29:365–70. [PubMed: 22924643]
 51. Barber SA, Gama L, Dudaronek JM, et al. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model. *J Infect Dis*. 2006;193:963–70. [PubMed: 16518758]
 52. Desplats P, Dumaop W, Smith D, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. *Neurology*. 2013;80:1415–23. [PubMed: 23486877]
 53. Chompre G, Cruz E, Maldonado L, et al. Astrocytic expression of HIV-1 nef impairs spatial and recognition memory. *Neurobiol Dis*. 2013;49:128–36. [PubMed: 22926191]
 54. Churchill MJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. *Ann Neurol*. 2009;66:253–8. [PubMed: 19743454]
 55. Ranki A, Nyberg M, Ovod V, et al. Abundant expression of HIV nef and rev proteins in brain astrocytes *in vivo* is associated with dementia. *AIDS*. 1995;9:1001–8. [PubMed: 8527071]
 56. Chauhan A, Mehla R, Vijayakumar TS, Handy I. Endocytosis-mediated HIV-1 entry and its significance in the elusive behavior of the virus in astrocytes. *Virology*. 2014;456–457:1–9.
 57. Chauhan A. Enigma of HIV-1 latent infection in astrocytes: an *in-vitro* study using protein kinase C agonist as a latency reversing agent. *Microbes Infect*. 2015;17:651–9. [PubMed: 26043820]
 58. Boutet A, Salim H, Taoufik Y, et al. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4. *Glia*. 2001;34:165–77. [PubMed: 11329179]

59. Dewhurst S, Sakai K, Bresser J, et al. Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV. *J Virol.* 1987;61:3774–82. [PubMed: 2446007]
60. Barat C, Proust A, Deshiere A, et al. Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency. *Glia.* 2018;66:1363–81. [PubMed: 29464785]
61. Atwood WJ, Tornatore CS, Meyers K, Major EO. HIV-1 mRNA transcripts from persistently infected human fetal astrocytes. *Ann N Y Acad Sci.* 1993;693:324–5. [PubMed: 8267293]
62. Schneider M, Tigges B, Meggendorfer M, et al. A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain. *AIDS.* 2015;29:1147–59. [PubMed: 26035317]
63. Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. *Neuron.* 2011;70:687–702. [PubMed: 21609825]
64. Bonaguidi MA, Song J, Ming GL, Song H. A unifying hypothesis on mammalian neural stem cell properties in the adult hippocampus. *Curr Opin Neurobiol.* 2012;22:754–61. [PubMed: 22503352]
65. Gonzalez-Perez O, Quiñones-Hinojosa A, Garcia-Verdugo JM. Immunological control of adult neural stem cells. *J Stem Cells.* 2010;5:23–31. [PubMed: 20861925]
66. Luo C, Koyama R, Ikegaya Y. Microglia engulf viable newborn cells in the epileptic dentate gyrus. *Glia.* 2016;64:1508–17. [PubMed: 27301702]
67. Sato K. Effects of microglia on neurogenesis. *Glia.* 2015;63:1394–405. [PubMed: 26010551]
68. Borsini A, Cattaneo A, Malpighi C, et al. Interferon-alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-dependent mechanisms. *Int J Neuropsychopharmacol.* 2018;21:187–200. [PubMed: 29040650]
69. Zhang K, Xu H, Cao L, Li K, Huang Q. Interleukin-1 β inhibits the differentiation of hippocampal neural precursor cells into serotonergic neurons. *Brain Res.* 2013;1490:193–201. [PubMed: 23085314]
70. Crampton SJ, Collins LM, Toulouse A, Nolan YM, O’Keeffe GW. Exposure of foetal neural progenitor cells to IL-1 β impairs their proliferation and alters their differentiation-a role for maternal inflammation? *J Neurochem.* 2012;120:964–73. [PubMed: 22192001]
71. Peng H, Sun L, Jia B, et al. HIV-1-infected and immune-activated macrophages induce astrocytic differentiation of human cortical neural progenitor cells via the STAT3 pathway. *PLoS One.* 2011;6:e19439. [PubMed: 21637744]
72. Zhang Y, Liu J, Yao S, et al. Nuclear factor kappa B signaling initiates early differentiation of neural stem cells. *Stem Cells.* 2012;30:510–24. [PubMed: 22134901]
73. Johansson S, Price J, Modo M. Effect of inflammatory cytokines on major histocompatibility complex expression and differentiation of human neural stem/progenitor cells. *Stem Cells.* 2008;26:2444–54. [PubMed: 18635871]
74. Mäkelä J, Koivuniemi R, Korhonen L, Lindholm D. Interferon-gamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells. *PLoS One.* 2010;5:e11091. [PubMed: 20559421]
75. Granowitz EV, Saget BM, Wang MZ, Dinarello CA, Skolnik PR. Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein Type 1. *Mol Med.* 1995;1:667–77. [PubMed: 8529133]
76. He H, Sharer LR, Chao W, et al. Enhanced human immunodeficiency virus Type 1 expression and neuropathogenesis in knockout mice lacking Type I interferon responses. *J Neuropathol Exp Neurol.* 2014;73:59–71. [PubMed: 24335529]
77. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus Type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. *Proc Natl Acad Sci U S A.* 1989;86:5974–8. [PubMed: 2762307]
78. Roff SR, Noon-Song EN, Yamamoto JK. The significance of interferon- γ in HIV-1 pathogenesis, therapy, and prophylaxis. *Front Immunol.* 2014;4:498. [PubMed: 24454311]
79. Zhang M, Clausell A, Robinson T, et al. Host factor transcriptional regulation contributes to preferential expression of HIV Type 1 in IL-4-producing CD4 T cells. *J Immunol.* 2012;189:2746–57. [PubMed: 22875803]

80. Putatunda R, Zhang Y, Li F, et al. Adult neurogenic deficits in HIV-1 tg26 transgenic mice. *J Neuroinflammation*. 2018;15:287. [PubMed: 30314515]
81. Fan Y, Gao X, Chen J, Liu Y, He JJ. HIV tat impairs neurogenesis through functioning as a notch ligand and activation of notch signaling pathway. *J Neurosci*. 2016;36:11362–73. [PubMed: 27807176]
82. Ferrell D, Giunta B. The impact of HIV-1 on neurogenesis: implications for HAND. *Cell Mol Life Sci*. 2014;71:4387–92. [PubMed: 25134912]
83. Ensoli F, Cafaro A, Fiorelli V, et al. HIV-1 infection of primary human neuroblasts. *Virology*. 1995;210:221–5. [PubMed: 7793075]
84. Rothenaigner I, Kramer S, Ziegler M, et al. Long-term HIV-1 infection of neural progenitor populations. *AIDS*. 2007;21:2271–81. [PubMed: 18090275]
85. Skowronska M, McDonald M, Velichkovska M, et al. Methamphetamine increases HIV infectivity in neural progenitor cells. *J Biol Chem*. 2018;293:296–311. [PubMed: 29158267]
86. Lawrence DM, Durham LC, Schwartz L, et al. Human immunodeficiency virus Type 1 infection of human brain-derived progenitor cells. *J Virol*. 2004;78:7319–28. [PubMed: 15220405]
87. Balinang JM, Masvekar RR, Hauser KF, Knapp PE. Productive infection of human neural progenitor cells by R5 tropic HIV-1: opiate co-exposure heightens infectivity and functional vulnerability. *AIDS*. 2017;31:753–64. [PubMed: 28099189]
88. Clarke JN, Lake JA, Burrell CJ, et al. Novel pathway of human immunodeficiency virus Type 1 uptake and release in astrocytes. *Virology*. 2006;348:141–55. [PubMed: 16445956]
89. Torres-Muñoz J, Stockton P, Tacoronte N, et al. Detection of HIV-1 gene sequences in hippocampal neurons isolated from postmortem AIDS brains by laser capture microdissection. *J Neuropathol Exp Neurol*. 2001;60:885–92. [PubMed: 11556545]
90. Schwartz L, Civitello L, Dunn-Pirio A, et al. Evidence of human immunodeficiency virus Type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. *J Neurovirol*. 2007;13:274–83. [PubMed: 17613718]
91. Deleage C, Chan CN, Busman-Sahay K, Estes JD. Next-generation in situ hybridization approaches to define and quantify HIV and SIV reservoirs in tissue microenvironments. *Retrovirology*. 2018;15:4. [PubMed: 29316956]
92. Gibellini L, Pecorini S, De Biasi S, et al. Exploring viral reservoir: the combining approach of cell sorting and droplet digital PCR. *Methods*. 2018;134–5:98–105.
93. Qian X, Nguyen HN, Song MM, et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. *Cell*. 2016; 165:1238–54. [PubMed: 27118425]
94. Krathwohl MD, Kaiser JL. HIV-1 promotes quiescence in human neural progenitor cells. *J Infect Dis*. 2004;190:216–26. [PubMed: 15216454]
95. Okamoto S, Kang YJ, Brechtel CW, et al. HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cellcycle withdrawal and G1 arrest. *Cell Stem Cell*. 2007;1:230–6. [PubMed: 18371353]
96. Toggas SM, Masliah E, Rockenstein EM, et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. *Nature*. 1994;367:188–93. [PubMed: 8114918]
97. Lee MH, Wang T, Jang MH, et al. Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease. *Neurobiol Dis*. 2011;41:678–87. [PubMed: 21146610]
98. Avraham HK, Jiang S, Fu Y, et al. The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. *Br J Pharmacol*. 2014;171:468–79. [PubMed: 24148086]
99. Avraham HK, Jiang S, Fu Y, et al. Impaired neurogenesis by HIV-1-gp120 is rescued by genetic deletion of fatty acid amide hydrolase enzyme. *Br J Pharmacol*. 2015;172:4603–14. [PubMed: 24571443]
100. Karanian DA, Karim SL, Wood JT, et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. *J Pharmacol Exp Ther*. 2007;322:1059–66. [PubMed: 17545313]

101. Mishra M, Taneja M, Malik S, Khalique H, Seth P. Human immunodeficiency virus Type 1 tat modulates proliferation and differentiation of human neural precursor cells: implication in neuroAIDS. *J Neurovirol.* 2010;16:355–67. [PubMed: 20839920]
102. Chao J, Yang L, Yao H, Buch S. Platelet-derived growth factor-BB restores HIV tat-mediated impairment of neurogenesis: role of GSK-3 β / β -catenin. *J Neuroimmune Pharmacol.* 2014;9:259–68. [PubMed: 24248537]
103. Kim BO, Liu Y, Ruan Y, et al. Neuropathologies in transgenic mice expressing human immunodeficiency virus Type 1 tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. *Am J Pathol.* 2003;162:1693–707. [PubMed: 12707054]
104. Fan Y, Timani KA, He JJ. STAT3 and its phosphorylation are involved in HIV-1 tat-induced transactivation of glial fibrillary acidic protein. *Curr HIV Res.* 2015;13:55–63. [PubMed: 25613134]
105. Kesby JP, Markou A, Semenova S, Translational Methamphetamine AIDS Research Center (TMARC) Group. Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. *Eur Neuropsychopharmacol.* 2015;25:141–50. [PubMed: 25476577]
106. Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP. Expression of HIV-tat protein is associated with learning and memory deficits in the mouse. *Behav Brain Res.* 2012;229:48–56. [PubMed: 22197678]
107. Hahn YK, Paris JJ, Lichtman AH, et al. Central HIV-1 tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β -arrestin 2 activity in the forebrain. *Neurobiol Dis.* 2016;92: 124–36. [PubMed: 26845176]
108. Kesby JP, Markou A, Semenova S, TMARC Group. Effects of HIV/TAT protein expression and chronic selegiline treatment on spatial memory, reversal learning and neurotransmitter levels in mice. *Behav Brain Res.* 2016;311:131–40. [PubMed: 27211061]
109. Marks WD, Paris JJ, Schier CJ, et al. HIV-1 tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations. *J Neurovirol.* 2016;22:747–62. [PubMed: 27178324]
110. Curtis K, Rollins M, Carryl H, et al. Reduction of pyramidal and immature hippocampal neurons in pediatric simian immunodeficiency virus infection. *Neuroreport.* 2014;25:973–8. [PubMed: 25102373]
111. Dickie P, Felser J, Eckhaus M, et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. *Virology.* 1991;185:109–19. [PubMed: 1926769]
112. Reid W, Sadowska M, Denaro F, et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. *Proc Natl Acad Sci U S A.* 2001;98:9271–6. [PubMed: 11481487]
113. Vigorito M, LaShomb AL, Chang SL. Spatial learning and memory in HIV-1 transgenic rats. *J Neuroimmune Pharmacol.* 2007;2:319–28. [PubMed: 18040850]
114. Hestad KA, Menon JA, Silalukey-Ngoma M, et al. Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa. *J Nerv Ment Dis.* 2012;200:336–42. [PubMed: 22456588]

Figure 1.

Diagram of Hippocampal Neurogenesis Progression. Neural stem cells (NSC) and their progeny cells express stage-specific markers along the differentiative process. Specifically, Type 1a (quiescent) and 1b (active) NSCs express Nestin, GFAP, and Sox2. Additional transcription factors that are expressed are BLBP, Tbr2, Tis21, and MCM2. Type 1b NSCs, neural progenitor cells (NPC), and neuroblasts express Ki67, as they are proliferative in nature. NPCs lose GFAP expression, but retain Nestin, Sox2, Tbr2, Tis21, and MCM2 expression. Neuroblasts express doublecortin and lower levels of NeuroD, while granule neurons express β -tubulin III, Calbindin, NeuN, HuD, and MAP2.

Figure 2.

Working Model for Neural stem cells as an HIV-1 Reservoir. Productive infection of neural stem cells by HIV-1 results in integration of the proviral genome in these cells. As these neural stem cells differentiate into neural progenitor cells, the integrated provirus robustly reactivates and generates new virions. Neuroblasts and/or glioblasts could potentially harbor the integrated proviral genome, which could lead to viral integration in neurons, astrocytes, and oligodendrocytes. This new HIV-1 virus further infects microglia and infiltrating immune cells in the brain, which subsequently infects astrocytes. Astrocytic infection could result from direct cell-to-cell contact with infected immune cells or from stimulation from inflammatory cytokines, which could upregulate the receptors needed for HIV-1 infection. These astrocytes would release viral proteins that damage neuron, astrocyte, and oligodendrocyte function. In addition, these secreted virions could subsequently infect other neural stem cells, and re-seed that specific reservoir for further HIV-1 latency establishment.